859 related articles for article (PubMed ID: 17296915)
1. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
Sayao AL; Devonshire V; Tremlett H
Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
[TBL] [Abstract][Full Text] [Related]
2. The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis.
Sayao AL; Bueno AM; Devonshire V; Tremlett H;
Mult Scler; 2011 Nov; 17(11):1375-83. PubMed ID: 21677023
[TBL] [Abstract][Full Text] [Related]
3. Natural history of secondary-progressive multiple sclerosis.
Tremlett H; Yinshan Zhao ; Devonshire V
Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of clinical characteristics for 'benign' multiple sclerosis.
Ramsaransing GS; De Keyser J
Eur J Neurol; 2007 Aug; 14(8):885-9. PubMed ID: 17662009
[TBL] [Abstract][Full Text] [Related]
5. The natural history of primary progressive multiple sclerosis.
Koch M; Kingwell E; Rieckmann P; Tremlett H
Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Kurtkze expanded disability status scale and the functional independence measure: measures of multiple sclerosis-related disability.
Rabadi MH; Vincent AS
Disabil Rehabil; 2013; 35(22):1877-84. PubMed ID: 23600712
[TBL] [Abstract][Full Text] [Related]
7. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
[TBL] [Abstract][Full Text] [Related]
8. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
9. The natural history of primary progressive MS in British Columbia, Canada.
Tremlett H; Paty D; Devonshire V
Neurology; 2005 Dec; 65(12):1919-23. PubMed ID: 16380613
[TBL] [Abstract][Full Text] [Related]
10. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
Glad SB; Nyland HI; Aarseth JH; Riise T; Myhr KM
Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821
[TBL] [Abstract][Full Text] [Related]
12. Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009).
Shirani A; Zhao Y; Kingwell E; Rieckmann P; Tremlett H
Mult Scler; 2012 Apr; 18(4):442-50. PubMed ID: 21952097
[TBL] [Abstract][Full Text] [Related]
13. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
14. [Prognostics factors of renal failure in multiple sclerosis].
Viart L; Elalouf V; Petit J; Al Khedr A; Kristkowiak P; Saint F
Prog Urol; 2012 Dec; 22(16):1026-32. PubMed ID: 23178100
[TBL] [Abstract][Full Text] [Related]
15. Relapses and progression of disability in multiple sclerosis.
Confavreux C; Vukusic S; Moreau T; Adeleine P
N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
[TBL] [Abstract][Full Text] [Related]
16. Is late-onset multiple sclerosis associated with a worse outcome?
Tremlett H; Devonshire V
Neurology; 2006 Sep; 67(6):954-9. PubMed ID: 17000960
[TBL] [Abstract][Full Text] [Related]
17. Patient reported outcomes in benign multiple sclerosis.
Hviid LE; Healy BC; Rintell DJ; Chitnis T; Weiner HL; Glanz BI
Mult Scler; 2011 Jul; 17(7):876-84. PubMed ID: 21372114
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course?
Sidhom Y; Damak M; Riahi A; Hizem Y; Mrissa R; Mhiri C; Gouider R
J Neurol Sci; 2014 Aug; 343(1-2):110-4. PubMed ID: 24980939
[TBL] [Abstract][Full Text] [Related]
19. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis: clinical characteristics and disability progression in Moroccan children.
Ait Ben Haddou E; Alhyan M; Aasfara J; Regragui W; Ibrahimi A; Razine R; Abouqal R; Benomar A; Yahyaoui M
J Neurol Sci; 2014 Nov; 346(1-2):128-32. PubMed ID: 25216553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
